• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[14C-普瑞吡啶的给药途径、血液浓度、器官分布及体内排泄之间的关系]

[Relationship between means of administration, concentration in the blood, organ distribution and excretion of prespidin-14C from the body].

作者信息

Bogomolova N S, Suskova V S, Chernov V A, Serebriakov N G

出版信息

Farmakol Toksikol. 1976 Nov-Dec;39(6):742-6.

PMID:1024845
Abstract

Blood content, distribution among organs and tissues and passage from the organism of prospidine-C14 in rats, following its introduction per os and application to the skin in the form of an ointment, were studied. With these modes of introduction it is shown that prospidine and/or products of its biotransformation are capable of relatively quickly penerating through the wall of the gastro-intestinal tract and skin. However, specific radioactivity in the organs in such cases is scores of time lower than with intravenous administration. In case of the peroral introduction of the compound 72.3 per cent of the amount of the compound and/or of its metabolites administered are eliminated via the gastro-intestinal tract in two days.

摘要

研究了大鼠经口摄入和以软膏形式涂抹于皮肤后,丙哌卡因 - C14在大鼠体内的血药含量、在各器官和组织中的分布以及从机体的排出情况。通过这些给药方式表明,丙哌卡因和/或其生物转化产物能够相对较快地穿透胃肠道壁和皮肤。然而,在这种情况下,各器官中的比放射性比静脉注射时低数十倍。经口给予该化合物时,给药量的72.3%的化合物和/或其代谢产物在两天内通过胃肠道排出。

相似文献

1
[Relationship between means of administration, concentration in the blood, organ distribution and excretion of prespidin-14C from the body].[14C-普瑞吡啶的给药途径、血液浓度、器官分布及体内排泄之间的关系]
Farmakol Toksikol. 1976 Nov-Dec;39(6):742-6.
2
[Absorption and distribution of 14C-prospiding in the organs of rats after topical application on the skin and its content in the skin after intravenous injection].[皮肤局部应用后14C-丙磺舒在大鼠各器官中的吸收与分布及其静脉注射后在皮肤中的含量]
Vestn Dermatol Venerol. 1977 Jul(7):10-4.
3
[Prospidin-C14 blood level, distribution in the organs and tissues and excretion from the body of rats].[普罗司匹定-C14在大鼠体内的血药浓度、在器官和组织中的分布以及从体内的排泄情况]
Farmakol Toksikol. 1975 Nov-Dec;38(6):722-8.
4
Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.N,N-二乙基间甲苯酰胺在大鼠体内的吸收、分布、代谢及排泄
Drug Metab Dispos. 1996 Feb;24(2):156-63.
5
Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 5th communication: factors affecting percutaneous absorption in rats.新型维甲酸4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸的代谢与处置研究。第5篇通讯:影响大鼠经皮吸收的因素。
Arzneimittelforschung. 1997 Mar;47(3):270-5.
6
Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.普卢利沙星的药代动力学。首次通信:单次给药后在大鼠、狗和猴子体内的吸收、分布及排泄情况
Arzneimittelforschung. 1997 Mar;47(3):276-84.
7
Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.4-乙酰氨基苯乙酸的药代动力学。首次通讯:单次给予14C标记化合物后在小鼠、大鼠、狗和猴体内的吸收、分布、代谢及排泄情况
Arzneimittelforschung. 1990 Jul;40(7):800-5.
8
Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.新型类视黄醇4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸的代谢与处置研究。第四次通讯:在各种动物和人类中的吸收、代谢、排泄及血浆蛋白结合情况
Arzneimittelforschung. 1997 Mar;47(3):259-69.
9
[Study of distribution of Prospidin-C14 in the respiratory organs].[普罗斯皮丁-C14在呼吸器官中的分布研究]
Vestn Otorinolaringol. 1976 May-Jun(3):94-7.
10
Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen.
Arzneimittelforschung. 1981;31(4):679-90.